Nom du produit:2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

IUPAC Name:2,3,4,5-tetrafluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

CAS:2657617-90-6
Formule moléculaire:C12H14BF4NO2
Pureté:95%+
Numéro de catalogue:CM1075242
Poids moléculaire:291.05

Unité d'emballage Stock disponible Prix($) Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2657617-90-6
Formule moléculaire:C12H14BF4NO2
Point de fusion:-
Code SMILES:FC=1C(F)=C(F)C(B2OC(C)(C)C(O2)(C)C)=C(N)C1F
Densité:
Numéro de catalogue:CM1075242
Poids moléculaire:291.05
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

Column Infos

Glecirasib
On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.

Related Products